Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PKLBE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Dual-payload ADC (Mersana Therapeutics)
|
|||||
| Synonyms |
Dual-payload antibody-drug conjugate (Mersana Therapeutics); DP-ADC
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
12 (AF-HPA);4 (I-BiP)
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
AF-HPA+DNA monoalkylator I-BiP
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT); Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Synthemer platform, conjugating 4 of the loaded dual-payload scaffolds to the antibody.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.